IOMAI explained
| IOMAI |
| Predecessors: | --> |
| Founded: | 1997 |
| Founder: | Gregory Glenn |
| Areas Served: | --> |
IOMAI was a Biotech company founded in 1997 by Gregory Glenn M.D. of the Walter Reed Army Institute of Research and Dean Lewis, a World Bank employee. The company was the first to develop the concept of transcutaneous immunization, delivery of vaccines to the skin using a patch or similar method. This provided a means to stimulate robust immune responses safely as the skin patch-based immunization targeted Langerhans cells in the skin. The patch technology underwent extensive evaluation in the context of a traveler's diarrhea vaccine which entered Phase 3 pivotal trials in 2009. IOMAI was acquired by Intercell in 2008 and the technology was the subject of a development license to GSK in 2009. Dr. Glenn pioneered needle free delivery to the skin and spawned general interest in skin-targeting vaccine technologies, including intradermal delivery and the use of the heat labile toxin as an adjuvant and the adjuvant patch.
See also
References
- Frech . SA . Dupont . HL . Bourgeois . AL . McKenzie . R . Belkind-Gerson . J . Figueroa . JF . Okhuysen . PC . Guerrero . NH . Martinez-Sandoval . FG . Meléndez-Romero . JH . Jiang . ZD . Asturias . EJ . Halpern . J . Torres . OR . Hoffman . AS . Villar . CP . Kassem . RN . Flyer . DC . Andersen . BH . Kazempour . K . Breisch . SA . Glenn . GM . Jun 2008 . Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial . Lancet . 371 . 9629. 2019–25 . 10.1016/s0140-6736(08)60839-9 . 18554712. 32784525 .
- McKenzie . R . Bourgeois . AL . Frech . SA . Flyer . DC . Bloom . A . Kazempour . K . Glenn . GM . May 2007 . Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study . Vaccine . 25 . 18. 3684–91 . 10.1016/j.vaccine.2007.01.043 . 17313998.
- Glenn . GM . Villar . CP . Flyer . DC . Bourgeois . AL . McKenzie . R . Lavker . RM . Frech . SA . May 2007 . Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum . Infect Immun . 75 . 5. 2163–70 . 10.1128/iai.01740-06. 1865773 . 17261601.
- Glenn . GM . Thomas . DN . Poffenberger . KL . Flyer . DC . Ellingsworth . LR . Andersen . BH . Frech . SA . Dec 2009 . Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch . Vaccine . 27 . Suppl 6. G60–6 . 10.1016/j.vaccine.2009.10.031 . 20006142.
- Kenney . RT . Frech . SA . Muenz . LR . Villar . CP . Glenn . GM . Nov 2004 . Dose sparing with intradermal injection of influenza vaccine . N Engl J Med . 351 . 22. 2295–301 . 10.1056/nejmoa043540. 15525714 . free .
